Pink Biopharma

Company Overview

Snapshot

Founded in May 2018 by Rachel Eren, Yael Yoffe-Mizrahi, and Prof. Angel Porgador, Pink Biopharma operated with 1–10 employees. The company raised $3M across one funding round from FutuRx. A key milestone for the company was its development of a Monoclonal Antibody Therapy for Blood and Bone Cancer.

Business overview

Pink Biopharma was a drug-discovery company focused on developing a therapeutic monoclonal antibody. This antibody was designed as a natural-killer immune checkpoint inhibitor, targeting various cancers, particularly acute myeloid leukemia. The company operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the global pharmaceuticals market.

Company Intelligence Q&A

What was Pink Biopharma's primary focus?

Pink Biopharma focused on drug discovery, specifically developing a therapeutic monoclonal antibody as a natural-killer immune checkpoint inhibitor for various cancers, including acute myeloid leukemia.

When was Pink Biopharma founded?

Pink Biopharma was founded in May 2018.

Who were the founders of Pink Biopharma?

Pink Biopharma was co-founded by Rachel Eren, Yael Yoffe-Mizrahi, and Prof. Angel Porgador.

What was the total capital raised by Pink Biopharma?

Pink Biopharma raised a total of $3M across one funding round.

What was the status of Pink Biopharma?

Pink Biopharma ceased to operate in July 2021.